Glaucoma is a complex disease, and currently the only way to maintain patient health is by lowering intraocular pressure. Gene therapy to treat the disease is rapidly evolving. This is a much needed area of glaucoma treatment that can be applied to a variety of glaucoma types.
A major risk factor for glaucoma is high IOP and causes blindness primarily due to RGC damage and death. Therefore, Ace Therapeutics provides gene therapy development services for glaucoma, targeting candidate genes related to IOP and RGC, as well as many other related genes and pathways.
Services for Gene Therapy Development for Glaucoma
The vision loss due to RGC death in glaucoma is irreversible. Stem cells currently being investigated have great potential as a possible therapy for glaucoma, because they may have the potential to replace degenerated ocular tissue in glaucoma. We provide specialized services in glaucoma drug development, offers the opportunity to develop drugs for glaucoma using stem cell technology and stem cell-based therapies to restore vision loss due to glaucoma.
siRNA-based gene therapy is an emerging approach to glaucoma treatment. siRNA can be used to inhibit the expression of specific genes, thus providing a highly promising outcome for the treatment of ocular diseases, including glaucoma. Based on this, we utilize siRNA-based gene silencing strategies to treat glaucoma, providing researchers with development services to study the composition and mechanisms of siRNA drugs, offering solutions to the fundamental challenges faced during development.
In glaucoma, mitochondrial dysfunction is also an important physiopathological process. Oxidative stress triggers neuronal death in glaucoma, suggesting that mitochondria are involved in accelerating the loss of RGC as a major endogenous source of reactive oxygen species (ROS). We are dedicated to developing drug targets and gene therapies to improve mitochondrial function in glaucoma, providing meaningful solutions in the quest for improved gene therapy for glaucoma.
Developing gene delivery systems to deliver nucleic acid drugs to the eye has become a challenge. There are two general methods of delivery, including non-viral vectors and viral vectors. Both approaches have advantages and disadvantages, and the choice of a safe and efficient delivery system is of great importance for gene therapy. We offer gene delivery system development services for glaucoma gene therapy to ensure the transfer of genes to target cells and to advance the translational application of gene therapy.
Research Procedures for Gene Therapy for Glaucoma
- The type of glaucoma that requires gene therapy development is determined based on the client's needs. For different types of glaucoma, we will recommend different appropriate gene therapy programs.
- Select the target tissues. Other tissues such as ONH, ciliary body, sclera, etc. can also be used as gene targets.
- Select therapeutic genes. We can provide genomic analysis or directly select appropriate genes from candidate genes that are genetically linked to glaucoma to those involved in the relevant pathway.
- Select a gene delivery vector. You can visit our gene delivery system development services page. We will provide the correct delivery method with high transduction efficiency.
- Validate the effect. Select appropriate animal models for effect analysis and drug function analysis.
Collaborate with Us
We are committed to the development of gene therapy for glaucoma and look forward to your collaboration with us to develop more personalized, effective and friendly drugs, and even cures, which will improve the populations suffering from the effects of glaucoma.
For more detailed services, please contact us.
Reference
- Borrás T. The Pathway From Genes to Gene Therapy in Glaucoma: A Review of Possibilities for Using Genes as Glaucoma Drugs. Asia Pac J Ophthalmol (Phila), 2017, 6(1):80-93.